Clinical trials
Metastatic Uveal Melanoma clinical trials
Below are recruiting metastatic uveal melanoma clinical trials, each written for real people, not researchers. We’re tracking 39 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06940739RecruitingPhase 1/Phase 2
IOV-3001 and lifileucel for advanced melanoma
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
Denver, ColoradoAges 18–70 - NCT06586593Recruiting
Immunotherapy before surgery for advanced melanoma
This study looks at how well immunotherapy works before surgery for melanoma that has spread. If you have stage III or IV melanoma that can be removed, you may be able to join this trial.
AngersAges 18 years+ - NCT04424719Recruiting
Follow-up study for high-risk eye melanoma after treatment
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
ParisAges 18 years+ - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT06727630RecruitingPhase 1/Phase 2
A study of PRJ1-3024 for advanced or spreading melanoma
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT06246916RecruitingPhase 3
Testing a new immunotherapy combo for advanced melanoma
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Chandler, ArizonaAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT07237594RecruitingPhase 1
IL-17 blocker to prevent immunotherapy side effects
This trial tests whether a drug called secukinumab (an IL-17 blocker) can prevent or reduce severe side effects when you restart immunotherapy for advanced melanoma. It's for people who've had immune-related side effects before and need to continue treatment.
Durham, North CarolinaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic uveal melanoma?
- Yes. Clin2 currently lists 39 recruiting metastatic uveal melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic uveal melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic uveal melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.